- #ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shotThe molecules known as triple-Gs — agonists of GLP-1, GIP and glucagon — are drawing attention as data build suggesting they could be the most effective class of obesity drugs. Eli Lilly is leading…Endpoints · 1mo ago↗ source
- Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront dealIncyte plans to spend $1.25 billion upfront to buy Star Therapeutics' subsidiary Vega Therapeutics and its Phase 3 bleeding disorder candidate, the companies said Monday. The deal package also incl…Endpoints · 1mo ago↗ source
- Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appealTakeda has updated its financial results to reflect costs it could incur after losing an antitrust lawsuit concerning its laxative drug Amitiza. In May, the US District Court in Massachusetts rul…